Clinical trial NCT03322696 - References

Liver Cirrhosis — ADAMTS-13 LEVEL AS PREDICTIVE BIOMARKER FOR DEVELOPMENT OF PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS (ADAPTHRO)

Citation(s)

•   Amitrano L, Guardascione MA, Ames PR, Margaglione M, Iannaccone L, Brancaccio V, Balzano A
  Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. Thromb Haemost. 2006 Feb;95(2):221-3.
•   D'Amico M, Pasta F, Pasta L
  Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, in a Caucasian population. Gene. 2015 Aug 15;568(1):85-8. doi: 10.1016/j.gene.2015.05.034. Epub 2015 May 16.
•   Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR
  Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000 Oct 1;96(7):2364-8.
•   Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T
  FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005 Apr;129(1):93-100.
•   Lancellotti S, Basso M, Veca V, Sacco M, Riccardi L, Pompili M, De Cristofaro R
  Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Intern Emerg Med. 2016 Oct;11(7):959-67. doi: 10.1007/s11739-016-1467-x. Epub 2016 May 24.
•   Parikh S, Shah R, Kapoor P
  Portal vein thrombosis. Am J Med. 2010 Feb;123(2):111-9. doi: 10.1016/j.amjmed.2009.05.023. Review.
•   Ponziani FR, Zocco MA, Campanale C, Rinninella E, Tortora A, Di Maurizio L, Bombardieri G, De Cristofaro R, De Gaetano AM, Landolfi R, Gasbarrini A
  Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol. 2010 Jan 14;16(2):143-55. Review.
•   Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, Dell'era A, Pappalardo E, Mannucci PM
  Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005 Mar;41(3):603-8.
•   Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R
  Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646-9.
•   Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, Fujimura Y
  Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005 Aug 1;106(3):922-4. Epub 2005 Apr 26.
•   Yerdel MA, Gunson B, Mirza D, Karayalçin K, Olliff S, Buckels J, Mayer D, McMaster P, Pirenne J
  Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation. 2000 May 15;69(9):1873-81.
•   Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, Riccardi L, Lancellotti S, Santoliquido A, Flore R, Pompili M, Rapaccini GL, Tondi P, Gasbarrini GB, Landolfi R, Gasbarrini A
  Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009 Oct;51(4):682-9. doi: 10.1016/j.jhep.2009.03.013. Epub 2009 Apr 23.
•   Zöller B, Li X, Sundquist J, Sundquist K
  Familial risks of unusual forms of venous thrombosis: a nationwide epidemiological study in Sweden. J Intern Med. 2011 Aug;270(2):158-65. doi: 10.1111/j.1365-2796.2010.02326.x. Epub 2010 Dec 3.

STUDY OF THE ADAMTS-13 LEVEL AS PREDICTIVE BIOMARKER FOR DEVELOPMENT OF PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS

Details for clinical trial NCT03322696